Nashville, Tennessee
Phase 1 cancer trials in Nashville, TN
173 Phase 1 cancer studies are recruiting participants at sites in Nashville as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Nashville at a glance
- 173 studies are recruiting at a site in Nashville.
- By phase: Early Phase 1 (1), Phase 1 (88), Phase 1/2 (84).
- By sponsor: industry (165), university, hospital or other (6), government (2).
- By research area: Breast Cancer (64), Lung Cancer (61), Lymphoma (21), Prostate Cancer (13), Melanoma (10), Pancreatic Cancer (4).
- Most recent update to one of these records: November 17, 2026.
Breast cancer studies recruiting in Nashville
Basic details from each study's public record (the 30 most recently updated of 173). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Totus Medicines
- Study sites
- Sarah Cannon Cancer Center · Vanderbilt-Ingram Cancer Center
- Registry record
- NCT05683418 · updated
A Phase 1/2 Study of IAM1363 in HER2 Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study sites
- SCRI Oncology Partners · Vanderbilt Ingram Cancer Center
- Registry record
- NCT06253871 · updated
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study sites
- SCRI Oncology Partners · Tennessee Oncology, Pllc
- Registry record
- NCT06324357 · updated
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Vanderbilt Breast Center at One Hundred Oaks
- Registry record
- NCT05422794 · updated
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pliant Therapeutics, Inc.
- Study site
- Tennessee Oncology
- Registry record
- NCT06270706 · updated
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Stemline Therapeutics, Inc.
- Study site
- SCRI Oncology Partners Group
- Registry record
- NCT06638307 · updated
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study sites
- Greco Hainsworth Center for Research Tennessee Oncology · SCRI Oncology Partners
- Registry record
- NCT06827236 · updated
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07503808 · updated
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Immunomic Therapeutics, Inc.
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT07652242 · updated
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study sites
- Tennessee Oncology PLLC · Vanderbilt University Medical Center
- Registry record
- NCT03424005 · updated
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Phase 1
- Ages 19 and older
- All sexes
- Sponsor
- NiKang Therapeutics, Inc.
- Study site
- Sarah Cannon Research Institute (SCRI)
- Registry record
- NCT06586957 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Lung cancer studies recruiting in Nashville
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Institut de Recherches Internationales Servier
- Study site
- Sarah Canon Research Institute (SCRI) Oncology Partners
- Registry record
- NCT05786924 · updated
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- EpiBiologics
- Study site
- Sarah Cannon and HCA Research Institute
- Registry record
- NCT07462377 · updated
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT07277413 · updated
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Tennessee Oncology, PLLC
- Registry record
- NCT07730021 · updated
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
- Registry record
- NCT07903415 · updated
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
- Registry record
- NCT03460977 · updated
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Sarah Cannon Research Institute-Nashville-48456
- Registry record
- NCT04886804 · updated
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Bayer
- Study site
- Tennessee Oncology - Nashville Centennial Clinic
- Registry record
- NCT05099172 · updated
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Bayer
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06914128 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07020221 · updated
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT07227597 · updated
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
- Registry record
- NCT07090499 · updated
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- TRIANA Biomedicines, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07491497 · updated
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- SCRI Oncology Partners · Sarah Cannon Research Institute- Pharmacy
- Registry record
- NCT07519655 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Lymphoma studies recruiting in Nashville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Phase 1/2
- Up to age 22
- All sexes
- Sponsor
- PedAL BCU, LLC
- Study sites
- The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT04726241 · updated
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07520006 · updated
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Henry-Joyce Cancer Clinic ( Site 0115) · SCRI Oncology Partners ( Site 0100)
- Registry record
- NCT07519772 · updated
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Umoja Biopharma
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT07735533 · updated
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- Nuvalent Inc.
- Study site
- Sarah Cannon
- Registry record
- NCT05384626 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Nashville, TN on ClinicalTrials.gov.
Ask about studies near Nashville
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections